Dr Virginia Gretton has joined ReFaC, the REACH Facilitiation Company based in Crewe, Cheshire, UK, as technical officer.
Gretton was formerly regulatory manager at Harlan Laboratories, Derbyshire, where she was involved with all aspects of REACH registration and compliance. This covered data gap analysis, testing plans, exposure scenarios, risk assessment, classification and labelling, downstream user interaction, Safety Data Sheet preparation, as well as post-registration support.
In addition, Dr Gretton has held posts in academia and managed clinical research projects. She holds a DPhil in chemistry from the University of York, a BSc in combined science, and a post-graduate certificate in REACH management.
Peter Newport, ReFaC’s company secretary, said: ‘Virginia brings a wealth of practical regulatory experience, skills and technical knowledge to her new role, which will be invaluable in helping and advising clients on all aspects of REACH compliance.’
ReFaC hires Dr Virginia Gretton as technical officer
Has experience with all aspects of REACH registration
You may also like
Regulatory
FDA rejects Summit Therapeutics’ ivonescimab lung cancer drug
The US regulator has issued a complete response letter for the PD-1/VEGF bispecific antibody, citing a lack of statistically significant overall survival benefit in a Phase III trial despite improvements in progression-free survival
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)
How the enterprise trap is set: familiar platforms, borrowed requirements and hidden validation costs can turn seemingly safe purchasing decisions into costly operational burdens
Regulatory
EU combination products: MDR, article 117 and drug-device approval risks
Bringing a drug-device combination product to market in Europe requires more than a strong pharmaceutical dossier and a functional delivery device. Companies must align two different development models, satisfy EU MDR expectations, manage notified-body involvement, and demonstrate that the drug and device work safely as one integrated product
Regulatory
Is your combination product really submission-ready?
A pharmaceutical team may consider a combination product nearly ready because the clinical, stability, quality, and drug data are in place. At the same time, the device team may still be completing design verification, usability studies, risk-management activities, or notified-body preparation
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.